LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Search

Novocure Ltd

Closed

SectorHealthcare

17.96

Overview

Share price change

24h

Current

Min

17.81

Max

17.96

Key metrics

By Trading Economics

Income

-47M

-71M

Sales

-295K

174M

EPS

-0.62

Profit margin

-40.871

Employees

1,605

EBITDA

-29M

-63M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+45.71% upside

Dividends

By Dow Jones

Next Earnings

23 Jul 2026

Market Stats

By TradingEconomics

Market Cap

548M

2B

Previous open

17.96

Previous close

17.96

News Sentiment

By Acuity

50%

50%

159 / 345 Healthcare

Novocure Ltd Chart

Past performance is not a reliable indicator of future results.

Related News

12 Feb 2026, 15:08 UTC

Hot Stocks

Stocks to Watch Thursday: Cisco, McDonald's, AppLovin -- WSJ

Peer Comparison

Price change

Novocure Ltd Forecast

Price Target

By TipRanks

45.71% upside

12 Months Forecast

Average 26.17 USD  45.71%

High 48 USD

Low 17 USD

Based on 6 Wall Street analysts offering 12 month price targets forNovocure Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Sentiment

By Acuity

159 / 345 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
help-icon Live chat